Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer ; volume:23 ; number:1 ; day:5 ; month:1 ; year:2024 ; pages:1 ; date:12.2024
Molecular cancer ; 23, Heft 1 (5.1.2024), 1, 12.2024
- Urheber
-
Xing, Fei
Gao, Hongli
Chen, Guanglei
Sun, Lisha
Sun, Jiayi
Qiao, Xinbo
Xue, Jinqi
Liu, Caigang
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-023-01918-4
- URN
-
urn:nbn:de:101:1-2024031820594397089145
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Xing, Fei
- Gao, Hongli
- Chen, Guanglei
- Sun, Lisha
- Sun, Jiayi
- Qiao, Xinbo
- Xue, Jinqi
- Liu, Caigang
- SpringerLink (Online service)
Ähnliche Objekte (12)
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer